Race Oncology (ASX:RAC) Jumps 21% as RC220 Clears Another Safety Milestone

Third Patient Dosed, No Toxicity, Dose Escalation Next

Race Oncology(ASX: RAC) rose 21% after successfully dosing its third patient with RC220 in the CPACS study for anti-cancer synergy.

This took place in the company’s Phase 1 trial at Queen Mary Hospital in Hong Kong. The patient received a 40mg/m² dose, with no side effects reported.

Importantly, no dose-limiting toxicities have been observed in the study so far, which is a positive early sign for the safety profile of the treatment.

This is crucial because the therapy is being used alongside chemotherapy to help reduce some of the health complications that can come with treatment. That means both safety and efficacy are critical for the drug.

What Happens Next

The safety review committee will now assess the accumulated safety data from all three patients. If the trial is cleared to continue, which looks more likely given the clean safety record so far, the study should move to the next dose level of 80mg, double the current dose.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

The bigger picture for Race Oncology

RC220 is the core proprietary technology and formulation. It works by binding to DNA and RNA strands to inhibit MYC, which is one of the key regulators of cancer growth and helps tumours grow rapidly.

The CPACS trial is designed to show that RC220 can do two things at once. First, it may help protect the heart from the cardiotoxic effects of doxorubicin, a widely used chemotherapy drug. Second, it may enhance the anti-cancer effect of that treatment in patients with solid tumours.

That dual mechanism is the core commercial thesis. The drug is intended to be used alongside chemotherapy, with the goal of reducing some of the harmful side effects on the body while also improving the overall treatment response.

What this means for investors

The clean safety profile through three patients is still very early, but it is an encouraging sign and helps de-risk the move into the higher dose cohort.

Completing recruitment for the first cohort is an important procedural step, but investors should keep the stage of the trial in perspective. This is still only three patients at the lowest dose level.

The study is not expected to generate meaningful efficacy data until Stage 2. Before escalation can begin, the Safety Review Committee still needs to assess the data and formally clear the trial to proceed.

As a Phase 1 study, the main focus right now is safety and pharmacokinetics, not proof of efficacy.